[go: up one dir, main page]

BR9811573A - Benzyl compounds that inhibit vla-4 mediated leukocyte adhesion - Google Patents

Benzyl compounds that inhibit vla-4 mediated leukocyte adhesion

Info

Publication number
BR9811573A
BR9811573A BR9811573-1A BR9811573A BR9811573A BR 9811573 A BR9811573 A BR 9811573A BR 9811573 A BR9811573 A BR 9811573A BR 9811573 A BR9811573 A BR 9811573A
Authority
BR
Brazil
Prior art keywords
compounds
leukocyte adhesion
vla
mediated leukocyte
inhibit
Prior art date
Application number
BR9811573-1A
Other languages
Portuguese (pt)
Inventor
Eugene D Thorsett
Christopher M Semko
Michael A Pleiss
Louis John Lombardo
Andrei W Konradi
Francine S Grant
Darren B Dressen
Michael S Dappen
Original Assignee
Elan Pharm Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, American Home Prod filed Critical Elan Pharm Inc
Publication of BR9811573A publication Critical patent/BR9811573A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS DE BENZILA QUE INIBEM A ADESãO DE LEUCóCITOS MEDIADA POR VLA-4"<D>. São divulgados compostos que se ligam à VLA-4. Certos destes compostos também inibem a adesão de leucócitos e, em particular, a adesão de leucócitos mediada por VLA-4. Tais compostos são úteis no tratamento de doenças inflamatórias em um paciente mamífero, por exemplo, o ser humano, em que a doença pode ser, por exemplo, a asma, a doença de Alzheimer, a aterosclerose, a demência por AIDS, o diabetes, a doença inflamatória do intestino, a artrite reumatóide, a transplantação do tecido, a metástase do tumor e a isquemia miocárdica. Os compostos podem também ser administrados para o tratamento de doenças inflamatórias do cérebro, tais como a esclerose múltipla.Invention Patent: <B> "BENZIL COMPOUNDS INHIBIT VLA-4 MEDIATED LEUKOCYTE ADHESION" <D>. Compounds that bind to VLA-4 are disclosed. Certain of these compounds also inhibit leukocyte adhesion and, in particular, VLA-4 mediated leukocyte adhesion. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, for example, humans, in which the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory diseases of the brain, such as multiple sclerosis.

BR9811573-1A 1997-07-31 1998-07-31 Benzyl compounds that inhibit vla-4 mediated leukocyte adhesion BR9811573A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90358597A 1997-07-31 1997-07-31
PCT/US1998/015327 WO1999006436A1 (en) 1997-07-31 1998-07-31 Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (1)

Publication Number Publication Date
BR9811573A true BR9811573A (en) 2000-09-19

Family

ID=25417733

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811573-1A BR9811573A (en) 1997-07-31 1998-07-31 Benzyl compounds that inhibit vla-4 mediated leukocyte adhesion

Country Status (12)

Country Link
EP (1) EP1001975A1 (en)
JP (1) JP2001512138A (en)
KR (1) KR20010022413A (en)
CN (1) CN1265675A (en)
AU (1) AU8585198A (en)
BR (1) BR9811573A (en)
CA (1) CA2291473A1 (en)
HU (1) HUP0002680A3 (en)
IL (1) IL133635A0 (en)
NO (1) NO20000414L (en)
PL (1) PL338510A1 (en)
WO (1) WO1999006436A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
JP2002501518A (en) * 1997-05-30 2002-01-15 セルテック セラピューティックス リミテッド Anti-inflammatory tyrosine derivative
GB2365338B (en) * 1997-06-14 2002-04-03 Enzacta R & D Ltd Therapeutic systems
ATE249421T1 (en) 1997-06-23 2003-09-15 Tanabe Seiyaku Co INHIBITORS OF ALPHA4-BETA1-MEDIATED CELL ADHESION
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
JP2002504534A (en) 1998-02-26 2002-02-12 セルテック・セラピューティクス・リミテッド Phenylalanine derivatives as inhibitors of α4 integrin
US6521626B1 (en) * 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
ES2335643T3 (en) * 1999-12-16 2010-03-31 Biogen Idec Ma Inc. METHODS OF TREATMENT OF ISCHEMICAL OR HEMORRAGICAL INJURY OF THE CENTRAL NERVOUS SYSTEM USING ANTI-INTEGRIN ANTAGONISTS ALFA 4.
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
EP1244656A1 (en) 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
DE60130910T2 (en) 2000-04-17 2008-07-10 Ucb Pharma, S.A. ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
AU2001267753A1 (en) 2000-07-07 2002-01-21 Celltech R And D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&amp;D Limited 3-substituted isoquinolin-1-yl derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP2005022976A (en) * 2001-07-18 2005-01-27 Ajinomoto Co Inc Carboxylic acid derivative
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
ATE489951T1 (en) * 2002-03-28 2010-12-15 Merck Serono Sa THIAZOLIDINE-CARBONIC ACID AMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR
EP1592387A4 (en) * 2003-01-24 2009-05-06 Elan Pharm Inc Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
WO2005118538A2 (en) * 2004-04-20 2005-12-15 Amgen, Inc. Arylsulfonamides and uses as hydroxysteroid dehydrogenase
ATE546430T1 (en) * 2004-06-29 2012-03-15 Aventis Pharma Inc FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
NZ589086A (en) 2008-04-11 2012-09-28 Merrimack Pharmaceuticals Inc Human serum albumin (HSA) linkers and conjugates thereof
DK3202789T3 (en) 2010-04-16 2020-05-18 Biogen Ma Inc Anti-VLA-4 antibodies
CN102675244B (en) * 2011-03-16 2016-03-30 中国人民解放军军事医学科学院毒物药物研究所 Thiazine amide derivatives and in the purposes preparing neurodegenerative disease medicine
KR20170052526A (en) 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 Combination treatment for multiple sclerosis
KR102848349B1 (en) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 Anti-VLA-4 antibodies with reduced effector function
ES2987796T3 (en) 2018-10-30 2024-11-18 Gilead Sciences Inc N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
KR102641718B1 (en) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN112969504B (en) 2018-10-30 2024-04-09 吉利德科学公司 Compounds for inhibiting α4β7 integrin
MX2021005050A (en) 2018-10-30 2021-06-15 Gilead Sciences Inc QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS.
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04154732A (en) * 1990-10-18 1992-05-27 Nippon Kayaku Co Ltd Optical resolution method
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
NO20000414L (en) 2000-03-28
IL133635A0 (en) 2001-04-30
EP1001975A1 (en) 2000-05-24
CN1265675A (en) 2000-09-06
NO20000414D0 (en) 2000-01-27
KR20010022413A (en) 2001-03-15
HUP0002680A2 (en) 2001-07-30
HUP0002680A3 (en) 2001-12-28
AU8585198A (en) 1999-02-22
PL338510A1 (en) 2000-11-06
JP2001512138A (en) 2001-08-21
WO1999006436A1 (en) 1999-02-11
CA2291473A1 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
BR9811573A (en) Benzyl compounds that inhibit vla-4 mediated leukocyte adhesion
BR9811569A (en) Compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811598A (en) &#34;carbamyloxy compounds that inhibit vla-4-mediated leukocyte adhesion&#34;.
BR9811594A (en) Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion
BR9812111A (en) Dipeptide and related compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811599A (en) Dipetid compounds that inhibit vla-4 mediated leukocyte adhesion
BR9812114A (en) Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion
BR9812118A (en) 4-Amino-phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion
BR0007663A (en) Acyl derivatives for use in the treatment of diseases related to vla-4
BRPI0513143A (en) multivalent vla-4 antagonists comprising polymeric moieties
ECSP045425A (en) HETEROCYCLIC COMPOUNDS THAT INHIBIT THE ADHESION OF LEUKOCYTES THROUGH INTEGRINS a4
EA200401561A1 (en) HETEROARRYLIC COMPOUNDS THAT INHIBIT MEDIATED ГР4-INTEGRINES leukocyte adhesion
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
ATE264298T1 (en) ALPHA-AMINOACETIC ACID DERIVATIVES AS ALPHA 4 BETA 7 RECEPTOR ANTAGONISTS
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
AR029611A1 (en) COMPOUNDS THAT INHIBIT THE ADHESION OF LEUCOCITS INTERMEDIATE BY VLA-4
AR026105A1 (en) HETEROARILO, HETEROCICLICO AND ILO COMPUTERS THAT

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]